New antihemorrhagic agents: a novel antifibrinolytic strategy

  • Hemorrhage is a leading cause of death and cost associated with blood transfusion.

  • There is a need for the improvement of current treatments of bleeding associated with  surgery, trauma, intracerebral hemorrhage (ICH) or other tissue damages.

  • A novel target involved in fibrinolysis has been identified.

  • Proprietary novel compounds to prevent major bleeding have been developed:

    • Small molecule entity (SME).

    • Efficacy: 30,000 times more effective than the currently available therapies.

    • Safety: No thrombus formation and no impact on coagulation.

  • Primary Indication: prophylaxis and acute treatment of bleeding in cardiac surgery.

>> Download information


Programas de investigación

Programas de investigación en los que puede participar con el CIMA

Acuerdos y programas de investigación del CIMA [PDF]

"CIMA Lab Diagnostics"


Su objetivo es optimizar con el máximo nivel de calidad e innovación el abanico de diagnósticos genéticos e inmunofenotípicos que se desarrollan en diferentes laboratorios de la Universidad de Navarra.

Ir a empresas

Contacta con nosotros

Contacto:
Centro de Investigación Médica Aplicada (CIMA)
Avenida Pío XII, 55
31008 Pamplona
España

+34 948 194700
cima@unav.es